FDA Approves Keytruda for Relapsed/Refractory PMBCL

The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adults and children primary mediastinal large B-cell lymphoma that is refractory or has relapsed after two or more prior lines of therapy.